Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression.
Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.
Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.
Location: United States, Maryland, Germantown
Employees: 1-10
Total raised: $40M
Founded date: 2013
Investors 3
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
| - | TEDCO | tedcomd.co... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.02.2021 | Series C | $40M | - |
Mentions in press and media 6
| Date | Title | Description |
| 30.10.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 10.08.2021 | Seraxis appoints Shelley Hartman, Jerry Baty and MJ Choi to the Board of Directors | |
| 23.02.2021 | Capstone Headwaters Advises Seraxis on $40M Series C Financing Round | Capstone Headwaters, a leading middle market investment banking firm, advised Seraxis, Inc., a biotech company developing a cell replacement therapy for insulin-dependent diabetes, on its recently announced completion of a $40M Series C Pre... |
| 10.02.2021 | Seraxis Snags $40M in Series C Funding | GERMANTOWN, MD, Seraxis announced a $40M Series C private financing round led by Eli Lilly and Company, with participation from Frazier Healthcare Partners, Polaris Ventures, JDRF T1D Fund, and other investors. >> Click here for mo... |
| 09.02.2021 | Seraxis Closes $40M Series C Financing Round | William Rust, PhD, Chief Executive Officer and Founder, Seraxis Seraxis, a Germantown, Md.-based biotech company developing a cell replacement therapy for insulin-dependent diabetes, closed a $40M Series C financing round. The round was led... |
| 09.02.2021 | Seraxis Closes $40M Series C | Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes today announced the successful closing of a $40M Series C private financing round. The financing was led by Eli Lilly and Company, with particip... |